New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 30, 2013
10:55 EDTFDX, FDX, LLY, LLYSenate Finance Committee to hold a hearing
The Committee holds a hearing entitled, "Transatlantic Trade and Investment Partnership: Achieving the Potential". Participants include Executive Vice President Ducker of FedEx (FDX) and Senior Vice President Ricks of Eli Lilly (LLY) at the hearing being held on October 30 at 11 am. Webcast Link
News For FDX;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 5, 2015
10:04 EDTLLYEli Lilly DMD treatment granted orphan status
Subscribe for More Information
07:48 EDTFDXMacro environment positive for FedEx, says UBS
Subscribe for More Information
May 4, 2015
07:26 EDTLLYWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
May 1, 2015
10:25 EDTLLYEli Lilly call activity attributed to takeover speculation
Subscribe for More Information
10:14 EDTLLYRumor: Eli Lilly strength attributed to takeover speculation
07:43 EDTLLYExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
05:21 EDTFDXFedEx, TNT Express confirm 'timely progress' being made in takeover
Subscribe for More Information
April 29, 2015
10:39 EDTLLYCiti analyst says outlook still strong for big pharma
Subscribe for More Information
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:16 EDTLLYPfizer downgraded to Neutral from Buy at Citigroup
Citigroup analyst Andrew Baum downgraded Pfizer (PFE) to Neutral citing the stock's "strong" relative outperformance this year. Buam prefers prefer Eli Lilly (LLY), which he upgraded this morning to Buy, and Bristol-Myers (BMY) among large-cap U.S. Pharmaceuticals. He keeps a $37 price target for Pfizer shares.
06:13 EDTLLYEli Lilly upgraded to Buy with $100 target at Citigroup
Citigroup analyst Andrew Baum upgraded Eli Lilly to Buy from Neutral and raised his price target for shares to $100 from $66. The changes come after Baum increased his risk-adjusted peak sales estimate for Lilly's heart disease drug evacetrapib to $3.8B from $1.0B. The analyst also believes the company's oncology molecules abemaciclib and galunisertib are "high quality" and "under-appreciated." Shares of Lilly closed yesterday up 29c to $71.18.
April 27, 2015
06:19 EDTLLYPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
16:29 EDTLLYEli Lilly receives fourth FDA approval for CYRAMZA
Subscribe for More Information
April 23, 2015
09:52 EDTLLYEli Lilly sees at least $200M in savings from Novartis Animal Health acquisition
09:33 EDTLLYEli Lilly sees stronger doller hurting FY15 revenue by 7.5%
Subscribe for More Information
06:27 EDTLLYEli Lilly backs FY15 adjusted EPS view of $3.10-$3.20, consensus $3.15
Subscribe for More Information
06:26 EDTLLYEli Lilly reports Q1 EPS 87c, consensus 77c
Subscribe for More Information
April 22, 2015
15:50 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
14:35 EDTLLYEarnings Watch: Lilly to report Q1 results amid patent expirations
Eli Lilly and Company (LLY) is scheduled to report first quarter earnings before the market open on Thursday, April 23 with a conference call scheduled for 9:00 am ET. Lilly is a global pharmaceutical manufacturer that also has an animal health business segment. EXPECTATIONS: Analysts are looking for earnings per share of 77c on revenue of $4.62B, according to First Call. The consensus range for EPS is 64c-99c on revenue of $4.54B-$4.7B. LAST QUARTER: Eli Lilly reported fourth quarter EPS of 75c, compared to consensus estimates of 74c, on revenue of $5.12B against estimates of $5.2B. The company said it sees fiscal year 2015 EPS of $3.10-$3.20 on revenue of $19.5B-$20B. Lilly's CEO John Lechleiter commented on the quarter, "While Lilly's fourth quarter 2014 results continue to reflect the impact of patent expirations, we are moving to a period of growth led by diabetes, oncology and animal health. Despite the loss of significant revenue for Cymbalta and Evista following the expiration of our U.S. patents, we saw strong performance from many other products. At the same time, we made excellent progress with our innovation-based strategy, and we continue to advance our pipeline." STREET RESEARCH: On March 25, Suntrust raised its price target on Lilly shares to $95 from $80. After meeting with Eli Lilly's management, SunTrust said it expects the company's oncology and diabetes sales to double over the next five years. The firm is upbeat about the short-term outlook of the company's diabetes treatment, and says that its late stage autoimmune, Alzheimer's and cardiovascular treatments are advancing, while its Alzheimer's programs remain underappreciated. SunTrust said it expects the company's earnings CAGR to be in the mid teens between 2015-2020. It kept a Buy rating on Lilly shares. PRICE ACTION: Lilly shares are relatively flat since the company's last earnings report on January 30, and are trading up fractionally to $72.40 in midday trading ahead of Thursday's earnings release.
07:24 EDTFDXFedEx management to meet with Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use